1. Home
  2. FCF vs MLYS Comparison

FCF vs MLYS Comparison

Compare FCF & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Commonwealth Financial Corporation

FCF

First Commonwealth Financial Corporation

HOLD

Current Price

$20.94

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$26.92

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FCF
MLYS
Founded
1934
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.1B
IPO Year
1994
2023

Fundamental Metrics

Financial Performance
Metric
FCF
MLYS
Price
$20.94
$26.92
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$19.75
$48.67
AVG Volume (30 Days)
684.1K
1.5M
Earning Date
04-28-2026
05-06-2026
Dividend Yield
2.94%
N/A
EPS Growth
5.76
37.43
EPS
0.37
N/A
Revenue
N/A
N/A
Revenue This Year
$16.32
N/A
Revenue Next Year
$6.25
N/A
P/E Ratio
$57.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.00
$12.59
52 Week High
$21.41
$47.65

Technical Indicators

Market Signals
Indicator
FCF
MLYS
Relative Strength Index (RSI) 63.36 47.47
Support Level $18.07 $26.85
Resistance Level N/A $31.26
Average True Range (ATR) 0.36 1.37
MACD 0.03 -0.12
Stochastic Oscillator 71.06 24.77

Price Performance

Historical Comparison
FCF
MLYS

About FCF First Commonwealth Financial Corporation

First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: